Your session is about to expire
What is Glyxambi
EmpagliflozinThe Generic name of this drug
Treatment SummaryLinagliptin is a type of medication used to treat type 2 diabetes. It is unique from other diabetes medications in that it is not eliminated by the kidneys and its effects depend on the concentration of the drug in the body. It was approved by the FDA in 2011 and is manufactured by Boehringer Ingelheim.
Jardianceis the brand name
Glyxambi Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Jardiance
Empagliflozin
2014
24
Approved as Treatment by the FDA
Empagliflozin, also called Jardiance, is approved by the FDA for 5 uses including Cardiovascular Diseases and Physical Activity .Cardiovascular Diseases
Physical Activity
Used to treat Exercise in combination with Metformin
Type 2 Diabetes
Used to treat Type 2 Diabetes Mellitus in combination with Metformin
Diet
Used to treat Diet in combination with Metformin
Cardiovascular Mortality
Effectiveness
How Glyxambi Affects PatientsTaking 5mg of linagliptin stops the DPP-4 enzyme from working for up to 24 hours. As a result, the GLP-1 hormone increases, which helps the body better control blood sugar levels. This can be seen by lower levels of glucose and hemoglobin in the blood.
How Glyxambi works in the bodyLinagliptin works by blocking an enzyme called DPP-4. This stops the breakdown of two hormones: GLP-1 and glucose-dependant insulinotropic polypeptide (GIP). These hormones then stimulate the pancreas to release insulin while decreasing the release of glucagon. This leads to the liver not breaking down as much glycogen and more insulin to be released when blood sugar is high.
When to interrupt dosage
The recommended measure of Glyxambi is contingent upon the diagnosed disorder, including Physical Activity, Diet and Type 2 Diabetes. The dose likewise fluctuates as per the technique of delivery (e.g. Tablet - Oral or Tablet) mentioned in the table beneath.Condition
Dosage
Administration
Type 2 Diabetes
10.0 mg, 25.0 mg, , 5.0 mg, 12.5 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
Symptomatic Congestive Heart Failure
10.0 mg, 25.0 mg, , 5.0 mg, 12.5 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
Congestive Heart Failure
10.0 mg, 25.0 mg, , 5.0 mg, 12.5 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
Ejection fraction decreased
10.0 mg, 25.0 mg, , 5.0 mg, 12.5 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
Hospitalizations
10.0 mg, 25.0 mg, , 5.0 mg, 12.5 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
Monotherapy
10.0 mg, 25.0 mg, , 5.0 mg, 12.5 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
Cardiovascular Mortality
10.0 mg, 25.0 mg, , 5.0 mg, 12.5 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
Cardiovascular Diseases
10.0 mg, 25.0 mg, , 5.0 mg, 12.5 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
Physical Activity
10.0 mg, 25.0 mg, , 5.0 mg, 12.5 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
Therapeutic procedure
10.0 mg, 25.0 mg, , 5.0 mg, 12.5 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
Diet
10.0 mg, 25.0 mg, , 5.0 mg, 12.5 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
Warnings
Glyxambi ContraindicationsCondition
Risk Level
Notes
Kidney Failure
Do Not Combine
Renal Dialysis
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Empagliflozin may interact with Pulse Frequency
Common Glyxambi Drug Interactions
Drug Name
Risk Level
Description
Acetazolamide
Minor
Empagliflozin may increase the diuretic activities of Acetazolamide.
Ambrisentan
Minor
Empagliflozin may increase the hypotensive activities of Ambrisentan.
Amiloride
Minor
Empagliflozin may increase the diuretic activities of Amiloride.
Angiotensin 1-7
Minor
Empagliflozin may increase the hypotensive activities of Angiotensin 1-7.
Azosemide
Minor
Empagliflozin may increase the diuretic activities of Azosemide.
Glyxambi Toxicity & Overdose RiskThe recommended dosage of linagliptin does not change based on factors such as race, age, weight, sex, kidney health, or liver health. Clinical trials indicate that linagliptin is safe for people aged 10 to 18, but no studies have been done on younger children. Animal studies showed that female rats had an increased risk of lymphoma when taking a dose 200 times greater than the recommended amount. Other than this, linagliptin has not been shown to cause mutations, chromosome changes, or fertility problems.
Glyxambi Novel Uses: Which Conditions Have a Clinical Trial Featuring Glyxambi?
196 active trials are being conducted to assess the utility of Glyxambi in providing Physical Activity, Type 2 Diabetes and Diet management.Condition
Clinical Trials
Trial Phases
Type 2 Diabetes
192 Actively Recruiting
Phase 2, Not Applicable, Early Phase 1, Phase 1, Phase 4, Phase 3
Symptomatic Congestive Heart Failure
0 Actively Recruiting
Cardiovascular Mortality
0 Actively Recruiting
Monotherapy
1 Actively Recruiting
Phase 1, Phase 2
Cardiovascular Diseases
0 Actively Recruiting
Ejection fraction decreased
0 Actively Recruiting
Therapeutic procedure
0 Actively Recruiting
Congestive Heart Failure
312 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 1, Early Phase 1, Phase 4
Hospitalizations
2 Actively Recruiting
Not Applicable
Physical Activity
39 Actively Recruiting
Not Applicable, Phase 2, Phase 1, Early Phase 1
Diet
5 Actively Recruiting
Not Applicable
Glyxambi Reviews: What are patients saying about Glyxambi?
5Patient Review
2/4/2016 This weight loss treatment is very effective. I'm seeing great results, about 10 pounds lost per month.
5Patient Review
8/10/2015 I've been taking this medication since I was diagnosed with diabetes, and it's been really helpful in managing my blood sugar levels.
5Patient Review
10/26/2016 This medication is incredible! I've tried so many different diabetes medications and nothing has worked as well as this one. My readings have improved dramatically, and I couldn't be happier.
5Patient Review
6/6/2017 I've dropped 24lbs in just over 17 weeks and I feel great! My blood sugar is finally under control and I've even started working out and watching what I eat.
5Patient Review
9/7/2018 Glyxambi has been a great help to me. Not only have I lost sixty pounds since September 2015, but my a1c level has stayed at 6.1.
5Patient Review
12/26/2019 I much prefer this medication to Janumet 50/1000 mg
5Patient Review
5/12/2016 My A1C levels dropped from 11 to 7 in just three months, and I've been taking it for six with no negative side effects that I can see.
5Patient Review
3/24/2017 This medication has done wonders for me. I only had mild fatigue for the first few days, and since then I haven't experienced any negative side effects. Staying hydrated throughout the day is key while taking this medication.
5Patient Review
7/30/20154.3Patient Review
6/21/20153.3Patient Review
7/15/2016 Glyxambi lessened my A1c levels, but the joint pain and general achiness it caused was really not worth it. I'm going to have to tell my doctor that this isn't working out.
1.3Patient Review
5/7/2016 I had a lot of negative side effects from this medication, and it ultimately did not help me control my blood sugar levels. I was on it for approximately half a year.
1Patient Review
2/14/2018 Glyxambia was WAY too much for me. I felt insanely jittery and agitated after only one dose, which is not how I like to feel ever let alone first thing in the morning.
1Patient Review
4/9/2017 I had to stop taking this after only two days because I felt so sick. Nausea, vomiting, and fatigue made it impossible for me to function normally. Really disappointed.
Patient Q&A Section about glyxambi
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What is Glyxambi used for?
"This medication is a combination of 2 drugs, empagliflozin and linagliptin, which are used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems."
Answered by AI
What is the side effects of Glyxambi?
"The text lists a number of mild health problems that could include joint pain, nausea, increased thirst, a mild genital infection, a mild urinary tract infection, more frequent urination, a cold, or a sinus infection."
Answered by AI
Is Glyxambi metformin?
"Glyxambi (empaglifozin / linagliptin) is not a form of insulin, but rather a medication containing a combination of empagliflozin and linagliptin. These components work together to lower blood sugar levels and better regulate the insulin levels produced by your body after meals."
Answered by AI
Is Glyxambi good for diabetes?
"Empagliflozin (JARDIANCE) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.
Glyxambi can help improve blood sugar in adults with type 2 diabetes when used with diet and exercise, and can help reduce the risk of cardiovascular death in adults with type 2 diabetes who have known cardiovascular disease when empagliflozin is needed. Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that's indicated to help reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease."
Answered by AI